The findings, depicted in Figure 5I–P, unveiled that, with the exception of DHX30, PAAD patients with elevated expression levels of the remaining seven genes experienced significantly worse prognoses compared to those with lower expression levels. Here, DHX30 is linked to pancreatic adenocarcinoma.